GLC Biotechnology, Inc. (GLC), a molecular cancer diagnostics company, is an Ohio "C"
corporation and has been engaged in the development of cancer diagnostic tests with
supports of multiple SBIR grants since 2006. Currently, GLC is developing a noninvasive fecal
DNA test protected by exclusive intellectual property to target the multi-billion dollar
colorectal cancer (CRC) screening market.